Enteral High-Dose Docosahexaenoic Acid and Neurodevelopment in Extremely Preterm Infants: A Systematic Review and Meta-analysis
Files
(Published version)
Date
2025
Authors
Shepherd, E.
Ikeda, N.
Sullivan, T.R.
Marc, I.
Guillot, M.
McPhee, A.
Gibson, R.
Makrides, M.
Gould, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Current Developments in Nutrition, 2025; 9(9):107510-1-107510-11
Statement of Responsibility
Emily Shepherd, Naho Ikeda, Thomas R. Sullivan, Isabelle Marc, Mireille Guillot, Andrew J. McPhee, Robert A Gibson, Maria Makrides, Jacqueline F. Gould
Conference Name
Abstract
Background: Enteral high-dose docosahexaenoic acid (DHA) may be required for neurodevelopment, including cognition, of extremely preterm infants. High-level summative evidence is lacking. Objectives: This study aims to examine associations between enteral high-dose DHA during the neonatal period and neurodevelopment in infants born ≤29 wk of gestation. Methods: The following databases were searched (from inception to 11 April, 2024): CINAHL, Cochrane Library, Embase, Medline, Scopus, and Web of Science. Eligible randomized controlled trials (RCTs) in infants born ≤29 wk, assessing direct enteral administration ≥ 40 mg/kg/d DHA, or breast milk/formula with DHA ≥ 0.60% total fatty acids, reporting neurodevelopmental outcomes. Two reviewers independently screened articles, extracted data, and assessed quality using the Cochrane Handbook guidance. Data were pooled using fixed or random-effect meta-analyses. The primary outcome was global cognitive scores from a standardized test. Results: We screened 1978 articles and included 3 high-quality RCTs (2028 infants born ≤29 wk). Enteral high-dose DHA was not associated with overall differences in global cognition scores at a corrected age (CA) of 18–36 mo [3 RCTs, 638 children, mean difference (MD) 0.67; 95% confidence interval (CI): –1.80, 3.15; P = 0.59; I² = 0%] or CA of 5–7 y (2 RCTs, 852 children; MD: 2.22; 95% CI: –0.14, 4.57; P = 0.06; I² = 33%); however, benefit was observed in the largest RCT with a direct enteral emulsion (656 children, CA of 5 y, MD 3.45; 95% CI: 0.38, 6.52; P = 0.03). Associations with most secondary outcomes were not seen; however, high-dose DHA was associated with reduced mild motor (3 RCTs, CA of 18–36 mo) and cognitive (2 RCTs, CA of 5–7 y) impairment. No negative impacts were observed. Conclusions: Enteral high-dose DHA in extremely preterm infants was not associated with differences in global cognition scores on metaanalysis; however, higher scores were observed with the use of a direct emulsion. Results support contemporary recommendations. This trial was registered at PROSPERO as CRD42022382744 (https://www.crd.york.ac.uk/prospero/display_record.php? ID=CRD42022382744).
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Nutrition. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).